(Q37792116)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20868306%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Targeting the MET oncogene in cancer and metastases (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20868306%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20868306%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Silvia Benvenuti

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20868306%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Giulia M Stella

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20868306%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

language of work or name

English

0 references

publication date

26 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20868306%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

14 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20868306%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20868306%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20868306%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

1381-1394

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20868306%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

cites work

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Scatter-factor and semaphorin receptors: cell signalling for invasive growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Growth factors in development, transformation, and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Invasive growth: from development to metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Cancer therapy: can the challenge be MET?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Frequent amplification of the c-met gene in scirrhous type stomach cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

A novel germ line juxtamembrane Met mutation in human gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

MET as a target for treatment of chest tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

c-Met is a potentially new therapeutic target for treatment of human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Genetic link between cancer and thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Showering c-MET-dependent cancers with drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Drug development of MET inhibitors: targeting oncogene addiction and expedience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Structural basis for agonism and antagonism of hepatocyte growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Targeting the tumor and its microenvironment by a dual-function decoy Met receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

The Sema domain of Met is necessary for receptor dimerization and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Biochemical characterization of AMG 102: a neutralizing, fully human monoclonal antibody to human and nonhuman primate hepatocyte growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

"Active" cancer immunotherapy by anti-Met antibody gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

K252a inhibits the oncogenic properties of Met, the HGF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

N-(3-fluoro-4-(2-arylthieno[3,2-b]pyridin-7-yloxy)phenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Genetic analysis of the kinome and phosphatome in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Cancer genes and the pathways they control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Mutational analysis of the tyrosine kinome in colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Review: new biological insights in early clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Targeting cancer with small molecule kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Cancer. Addiction to oncogenes--the Achilles heal of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Screening for epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Activated ras and ret oncogenes induce over-expression of c-met (hepatocyte growth factor receptor) in human thyroid epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Cross-talk between the proto-oncogenes Met and Ron

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

The MET oncogene drives a genetic programme linking cancer to haemostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2010.522988

10.1517/13543784.2010.522988

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20868306%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

1 reference